JMYMED Technology Co., Ltd. est placuit ut nuntiare quod suum productum, Tirzepatide, habet feliciter complebitur ad medicamento Magister file (DMF) Registration cum US FDA (DMF Number: (IV) CXV, et accepit FDA in August II, MMXXIV.
Missam productio cum stabilis qualitas
Secundum jymmed technology scriptor senior administratione, mole productio of Tirzepatide activae pharmaceutical ingredient (API) potest pervenire kilogram campis. Productio batches sunt stabilis et continua, cum minimal variation inter batches, cursus consistent qualis.
Significant effectus in GLYCOSA et lipid reductionem
Tirzepatide est mundi primo probatus semel-weekly GIP / Glp-I receptor agonist. Ut Dual receptor agonist, potest eodem tempore obligant et activate et GLYCOSA-dependens insulinotropic polypeptide (GIP) receptor et glp-I receptor in humano corpore. Praeter minas GLYCOSA campester, reduces cibum attractio, corpus pondus et adipem contentus, et regulat lipids utendo. Singer ejus significant GLYCOSA-demissis et pondus-reducendo effectus, subgroup analyzes ex superant seriem studiis ostensum est quod Tirzepatide et amplio metabolicae Indicatores ut sanguinem pressura, sanguinem lipids, BMI et alvo circumferentiam, sanguinem lipids, BMI et alvo circumferentiam, sanguinem lipids, BMI, et alvo circumferentiam.
Multinational approbationes et promissum spe
Secundum ad pertinet notitia, in GLYCOSA-demissis Mounjaro fuit primus probatus per US FDA in May MMXXII ad curatio adultis cum type II diabete. Hoc est deinde accepit approbationes in EU, Iaponia et aliis regionibus. In November MMXXIII, et FDA et probatus pondus damnum indication in notam nomen Zepbound. In May MMXXIV, quod feliciter intravit in Chinese foro. Datum eius lata application spes et fortis supporting research notitia, tirzepatide est unum de maxime prominent peptide medicaménta hodie. Et venditionesque pervenit $ 5,163 billion in MMXXIII, et prima quarta pars MMXXIV sola vidit Sales of $ 2.324 billion, demonstrando mirum augmentum rate.
De jymmed
Shenzhen jymmed technology Co., Ltd. (Hereñafter referred to as jmed) in statutum est in MMIX, specialiter in investigationis, progressionem, productio et venditionesque peptides et peptide actis products. Et unum investigationis centrum et tres major productionem bases, jymmed est unus de maxima effectrix chemica synthesized peptide apis in Sinis. In Company scriptor core R & D quadrigis quatenus super XX annos experientia in peptide industria et feliciter Transierunt FDA inspectionibus bis. Jymmed scriptor comprehensive et efficens peptide industrialization ratio praebet customers a plena range of muneris, comprehendo ad progressionem et productionem therapeutic peptides, VETERINARIUS peptides, antimicrobial peptides, et regulatory peptides, tum adnotatione et regulatory Support.
Pelagus res actiones
1.Gomestis et International Registration of Peptide Apis
2.veterinary et COLOR peptides
3.Custom peptides et Cro, CMO, OEM Services
4.pdc medicamina (peptide-radionuclide, peptide-parva molecule, peptide, dapibus, peptide-rna)
Insuper et Tirzepatide, Jymed est Submitted Registration Fiction cum FDA et Cde pro pluribus aliis API products, comprehendo in currently popularibus GLP-1ra classis ut semaglutide et Liraglutide. Future customers per jymmed scriptor products poterit ad directe referat ad Cde adnotatione numero vel DMF file numerus cum submittendo adnotatione applications ad FDA aut Cde. Hoc autem significantly reducere tempus requiritur ad parat application documenta, tum iudicium et tempus et sumptus of productum recensionem.
Contact Us
Shenzhen jymmed technology Co., Ltd.
Oratio:8th & 9th contignationibus, aedificationem I, Shenzhen biomedical innovation IndustrialPark, No. XIV Jinhui Road, Kengzi subdristic, Pingshan regio, Shenzhen
Phone:LXXXVI 755-26612112
Website: http://www.jymedtech.com/
Post tempus: Aug-12-2024
